SILCS Diaphragm: a reusable system for microbicide gel delivery

SILCS DIAPHRAGM

The SILCS Diaphragm is a new single-size cervical barrier designed to expand women’s options for nonhormonal barrier protection, especially in low-resource settings. For women with an unmet need for family planning, access to a user-initiated, nonhormonal barrier method could improve their options. The single-size diaphragm simplifies supply and provision, which should reduce barriers that have limited use of traditional diaphragms. PATH incorporated user feedback from health care providers, women, and their partners to design special features that allow the device to be easy to use—even for new users.

SILCS AS A MULTIPURPOSE PREVENTION TECHNOLOGY

Since diaphragms are commonly used with contraceptive gel, there is interest in SILCS as a microbicide gel delivery system. Initial feasibility and acceptability studies, clinical research, and other introduction work are discussed below.

Using SILCS could offer several advantages:

- **Reduced messiness and leakage:** SILCS Diaphragm holds gel high in the vagina near the cervix, possibly leading to greater acceptability and less gel usage.
- **More consistent product use:** Women who use the SILCS Diaphragm for pregnancy prevention may use the microbicide gel products more consistently.
- **Less stigma:** SILCS Diaphragm is designed as a family-planning method, so there may be less stigma associated with use.
- **Lower cost:** As a reusable gel delivery system, the SILCS Diaphragm could be less expensive to use than vaginal applicators and have less environmental impact than disposable gel delivery systems.

INITIAL FEASIBILITY AND ACCEPTABILITY

Two exploratory studies in the United States have shown the feasibility and acceptability of using SILCS as a gel delivery system. The first study in 2007 evaluated the feasibility and ease of use of four gel delivery scenarios using two different gel volumes (3.5 and 5 ml per side) and application scenarios (sachet vs. sachet and applicator).

Nineteen women participated in this study, and all were able to successfully prepare, insert, and wear the device. Acceptability varied by scenario—with the least amount of gel most preferred (7 ml total). Recommendations from this study included loading gel on the cervical side only, using the least volume of gel required.

The second study in 2009 assessed gel distribution and retention in the vagina comparing gel delivered by the SILCS Diaphragm to a vaginal applicator. Women used three gel application scenarios—SILCS cervical side only (5 ml), SILCS cervical and vaginal sides (2.5 ml each), and vaginal applicator only (5 ml). Magnetic resonance imaging (MRI) scans assessed gel distribution at three time points (immediately after insertion, after simulated coitus, and six hours after simulated coitus). Qualitative data were collected on women’s experiences and preferences with these scenarios. MRI scans showed no significant difference in gel coverage between methods. Although all gel delivery scenarios were found to be feasible, acceptability differed by scenario. All three delivery systems were rated “relatively easy” to prepare and “easy” to insert; the applicator was rated as “easiest” potentially because it was more “familiar.”

SILCS —a single-size diaphragm that may also serve as a microbicide delivery system. Photo: PATH
ACCEPTABILITY—UNITED STATES AND SOUTH AFRICA

Following these studies, a pilot study was conducted in 2009 among 36 couples in the United States to evaluate acceptability of SILCS single- and double-sided gel delivery compared to a vaginal applicator. Couples used each delivery scenario during two acts of intercourse for a total of six sex acts. Acceptability data were collected from both women and their partners. All three gel delivery scenarios were found to be acceptable, although the vaginal applicator was rated more favorably for most attributes. This study clearly showed that in a population where women use non-barrier contraceptives and are at low risk of STIs, the vaginal applicator is more acceptable for gel delivery. However, further research of SILCS for microbicide delivery was recommended among populations that more closely reflect diverse potential user groups, such as women from high-HIV-prevalence settings and women who may be more likely to use a diaphragm for contraception.²

A couples’ acceptability study is planned in South Africa during 2014 to evaluate single-sided gel delivery using SILCS compared to a vaginal applicator. More than 100 women will evaluate both delivery scenarios during five acts of sex. Acceptability data will be collected from male partners. Study results will be available in early 2015.

EVALUATING DRUG DELIVERY AND BARRIER EFFECTIVENESS OF SILCS PLUS MICROBICIDE GEL

CONRAD, the regulatory sponsor of tenofovir (TFV) 1% gel, is scheduled to implement two clinical studies evaluating the use of SILCS with TFV.³ One study will evaluate the pharmacokinetics/pharmacodynamics of TFV delivered via SILCS. A second postcoital testing study will assess the barrier effectiveness of the SILCS Diaphragm used with TFV gel. These studies are expected to begin in 2014.

INTRODUCTION RESEARCH

The SILCS Diaphragm was launched in Europe in 2013 where it is marketed as the Caya® contoured diaphragm. PATH and partners are currently working to build awareness for SILCS in low-resource settings. Market research in South Africa found strong support for SILCS as a microbicide delivery system. Women are attracted to a product that could provide protection against unintended pregnancy, sexually transmitted infections, and HIV.

ACKNOWLEDGMENTS

PATH developed the SILCS Diaphragm with partners including CONRAD and researchers in multiple countries. In 2010 the technology was licensed to Kessel Marketing & Vertriebs GmbH for commercialization.

Support for the SILCS project is made possible by the generous support of the American people through the United States Agency for International Development (USAID) under the terms of the HealthTech Cooperative Agreement # AID-OAA-A-11-00051. The contents are the responsibility of PATH and do not necessarily reflect the views of USAID or the US Government.

For more information regarding SILCS, please contact:
Maggie Kilbourne-Brook, SILCS team leader
mkilbou@path.org.

For commercial inquiries, please contact:
Martin Kessel, Kessel Marketing & Vertriebs GmbH
kessel@kessel-marketing.de

REFERENCES


3. Page on Tenofovir Clinical Trials. CONRAD website. Available at: http://www.conrad.org/tenofovir-studies.html